Loading
Cellebrite DI Ltd. Stock: price and insider trades · United States
Cellebrite DI Ltd.: what insiders have been doing
Cellebrite DI Ltd., classified in the Technology sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Cellebrite DI Ltd. logged 35 filings by 19 insiders.
The flow runs one way only: 13 sales worth €4.4M, from 4 insiders, and no purchase. Biggest ticket of the year: €1.9M, sold by Hogan Thomas E. and made public on 13 August 2026 (0.073% of market cap).
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,814 companies, median 19 filings), a count of 35 filings is above the norm. The full history, which starts in 2026, counts no purchases against 13 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Core Scientific, Inc./tx and Gitlab Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
35
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
13 ops. · all time
Who traded when
BuySaleDavid Nicholas Gee6 sales
Marcus Jewell3 sales
Thomas E. Hogan3 sales
David Barter1 sale
Analyst consensus: bullish or bearish?
Analysts rate Cellebrite DI Ltd. Strong Buy (bullish), based on 7 analysts. Average price target: US$15.36.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,235 of 24,161 companies
63.6
score / 100
Value44
Quality83
FCF yld5.8%
Earn yld2.8%
EV/EBITDA27.1x
ROE12%
Gross mgn84%
Net mgn16%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.83
Analyst consensus
7 analystsStrong buy
US$12.50Target US$15.36(+42%)US$20.00
Income statement
RevenueUS$475.7M
Gross profitUS$400.5M84% margin
EBITDAUS$103.1M22% margin
Net incomeUS$77.8M11.4% margin
Valuation
PER (trailing)49.2x
PER (forward)16.6x
P/Book5.0x
Beta1.13
Balance sheet & cash
Market capUS$2.7B
Total debtUS$22.7M
Free Cash FlowUS$160.3M
Debt / Equity4%
Profitability & ownership
ROE12.4%
ROA3.9%
% insiders43.5%
% institutions53.3%
Last declaration on 7 October 2026
Declarations35 total
23,497 shares@ US$11.370.0093% mcap15.6% of flowOrdinary shares, par value NIS 0.00001SEC144:0001628280-26-065286
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001971298-26-000003:0
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001970748-26-000002:0
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001213900-26-104047:0
38,505 shares0Ordinary shares, par value NIS 0.00001SEC:0001628280-26-063560:0
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001628280-26-062371:0
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001628280-26-062373:0
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001628280-26-062375:0
15,190 shares0Ordinary shares, par value NIS 0.00001SEC:0001628280-26-062398:0
25,299 shares@ US$11.29340.0096% mcap6.9% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-059297:0
4,323 shares@ US$11.36050.0017% mcap31.6% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-058874:0
63,187 shares@ US$11.310.025% mcap100.0% of flowOrdinary shares, par value NIS 0.00001SEC144:0001628280-26-058620
2,198 shares@ US$11.24160.0008% mcap15.9% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-058628:0
12,562 shares@ US$11.24160.0048% mcap92.4% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-058632:0
31,728 shares@ US$10.440.011% mcap95.2% of flowOrdinary shares, par value NIS 0.00001SEC144:0001628280-26-057832
5,673 shares@ US$10.440.0020% mcap100.0% of flowOrdinary shares, par value NIS 0.00001SEC144:0001628280-26-057835
230 shares@ US$16.06780.0001% mcap2.4% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-056491:0
411 shares@ US$16.06780.0002% mcap4.4% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-056495:0
139,713 shares@ US$15.38610.073% mcap52.8% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-056875:1
339,484 shares0Ordinary shares, par value NIS 0.00001SEC:0001628280-26-056875:0
339,484 shares@ US$15.900.20% mcap100.0% of flowOrdinary shares, par value NIS 0.00001SEC144:0001628280-26-055716
1,045 shares@ US$15.640.0006% mcap4.8% of flowOrdinary shares, par value NIS 0.00001SEC144:0001628280-26-054582
41,734 shares@ US$16.37560.024% mcap100.0% of flowOrdinary shares, par value NIS 0.00001SEC:0001628280-26-047784:0
25 of 35 declarations
About Cellebrite DI Ltd.
Cellebrite DI Ltd. is a specialized digital intelligence software and services company listed on the NASDAQ under the ticker CLBT and operating as a U.S.-listed business with a dual operational footprint in Tysons Corner, Virginia, and Petah Tikva, Israel. For investors, it is best viewed as a technology company positioned at the intersection of cybersecurity, digital forensics and data analytics, serving both public-sector and enterprise customers. The company was founded in 1999 and has built its brand around tools that help investigators collect, process and analyze data from mobile devices, computers and cloud environments in order to accelerate case resolution and support evidence-based decision-making. ([cellebrite.com](https://cellebrite.com/en/about/?utm_source=openai))
Over time, Cellebrite has evolved from a pure digital forensics specialist into a broader “case-to-closure” platform provider. Its portfolio now spans evidence extraction, review, analysis and investigative collaboration, with Inseyets positioned as its flagship digital forensics offering. The company has also been investing in cloud and SaaS capabilities, and its 2025 acquisition of Corellium added Arm-based virtualization expertise, strengthening its technology stack and expanding its ability to support mobile research, security testing and advanced investigative workflows. ([investors.cellebrite.com](https://investors.cellebrite.com/news-releases/news-release-details/cellebrite-completes-acquisition-corellium-extending-industrys?utm_source=openai))
Read moreShow less
From a competitive standpoint, Cellebrite appears to benefit from meaningful installed-base advantages and deep institutional relationships. The company states that its technology has been purchased by approximately 6,900 public safety agencies and enterprises in more than 100 countries, with broad penetration across North American federal, state and local agencies as well as enterprise blue-chip accounts. That said, the business remains exposed to procurement cycles, regulatory scrutiny and compliance requirements, all of which are especially important in a market tied to law enforcement, national security and public-sector contracting. ([cellebrite.com](https://cellebrite.com/en/about/?utm_source=openai))
Recent developments have been constructive. In 2025 and early 2026, Cellebrite reported continued ARR and revenue growth, highlighted stronger adoption of its cloud and SaaS offerings, and introduced new seasonal releases for its digital investigation platform. The company also established Cellebrite Federal Solutions to better serve the U.S. federal government and said its Government Cloud achieved FedRAMP High authorization, which is an important credibility marker in federal procurement. For equity investors, the name offers a mix of recurring software economics, secular demand for investigative technology and ongoing product expansion, though budget timing and policy-sensitive public-sector spending remain key variables. ([investors.cellebrite.com](https://investors.cellebrite.com/news-releases/news-release-details/cellebrite-announces-record-fourth-quarter-and-full-year-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
